An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.

This study is investigating a new tablet medicine called IKT-001 for a condition known as pulmonary arterial hypertension (PAH). PAH is a serious disease where the blood vessels in your lungs become narrow, making it harder for your heart to pump blood through them. This can lead to symptoms like breathlessness, tiredness, and chest pain. Finding new and better treatments for PAH is very important to help people manage their symptoms and improve their quality of life.

The study is designed in a clever way, split into two main parts, but running together. In both parts, some participants will receive the new medicine, IKT-001, and others will receive a 'placebo'. A placebo looks exactly like the real medicine but contains no active ingredients – it's like a sugar pill. This is a standard way to make sure any improvements seen are genuinely due to the medicine being tested, and not just because someone expects to feel better. Neither you nor your doctor will know if you are receiving the real medicine or the placebo, which helps keep the study fair and unbiased.

The main goals of the study are to understand if IKT-001 is effective and safe. Specifically, researchers will be looking at how well the medicine reduces the pressure in the lungs and how much it improves a person's ability to walk. They will also check a range of other health markers, such as specific blood tests, changes in symptoms, how far people can walk in six minutes, and how the medicine affects their overall quality of life. By carefully collecting all this information, the researchers hope to determine if IKT-001 could become a valuable new treatment option for people living with PAH.